Home LiteratureArticle Details
PMID: 12191604 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2.

Pharmacology & therapeutics ·Vol. 93 ·No. 2-3 ·2002-00-00 ·Pages 113-24

Johnson LN, De Moliner E, Brown NR, Song H, Barford D, Endicott JA, Noble ME

Abstract

Components of the cell cycle machinery are frequently altered in cancer. Many of these alterations affect the cyclin-dependent kinases (CDKs) and their regulation. Staurosporine and 7-hydroxystaurosporine (UCN-01) are two natural product kinase inhibitors originally identified as potent protein kinase C inhibitors. Staurosporine is non-selective and too toxic for use in therapy, but UCN-01 shows greater selectivity, and is in clinical trials. We have determined the crystal structures of staurosporine bound to monomeric CDK2 and UCN-01 bound to active phospho-CDK2/cyclin A. Both compounds mimic the hydrogen bonds made by the adenine moiety of ATP, and both exploit the non-polar nature of the adenine-binding site. In the complex with UCN-01, a hydrogen-bonded water molecule is incorporated into the non-polar cavity, which provides a partial polar character in the environment of the 7-hydroxyl group. Comparison of the ATP-binding site of CDK2 with that of other kinases reveals that in Chk1 kinase, a major target for UCN-01 in the cell, one of the surrounding residues, Ala144 in CDK2, is a serine in Chk1, thus providing a possible explanation for the effectiveness of UCN-01 against this kinase. For cells to exit mitosis, the CDKs must be completely inactivated, firstly by the ubiquintin-mediated destruction of the cyclins, followed by dephosphorylation of phospho-Thr160 (in CDK2) catalysed by the kinase-associated phosphatase and protein phosphatase 2C. We describe the structure of phospho-CDK2 in complex with kinase-associated phosphatase, and discuss the substrate recognition promoted by interactions that are remote from the catalytic site.

MeSH Terms
CDC2-CDC28 Kinases Cyclin-Dependent Kinase 2 Cyclin-Dependent Kinase Inhibitor p21 Cyclin-Dependent Kinases/drug effects,metabolism,physiology Cyclins/metabolism,pharmacology Enzyme Inhibitors/metabolism,pharmacology Humans Molecular Biology Neoplasms/drug therapy,enzymology,metabolism Protein Serine-Threonine Kinases/drug effects,metabolism,physiology Staurosporine/metabolism,pharmacology Structure-Activity Relationship
Chemicals
CDKN1A protein, human Cyclin-Dependent Kinase Inhibitor p21 Cyclins Enzyme Inhibitors Protein Serine-Threonine Kinases CDC2-CDC28 Kinases CDK2 protein, human Cyclin-Dependent Kinase 2 Cyclin-Dependent Kinases Staurosporine
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Johnson Louise N
Laboratory of Molecular Biophysics, Department of Biochemistry, University of Oxford, Rex Richards Building, South Parks Road, OX1 3QU, Oxford, UK. louise@biop.ox.ac.uk
De Moliner Erika
Brown Nick R
Song Haiwei
Barford David
Endicott Jane A
Noble Martin E M
Article Info
Journal
Pharmacology & therapeutics
Abbr.
Pharmacol Ther
ISSN
0163-7258
Published
2002-00-00
Pages
113-24
Language
English
Region
England
NLM ID
7905840
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com